Clinical application of the Fricke-glucomannan gel dosimeter for high-dose-rate (192)Ir brachytherapy

Phys Med Biol. 2008 Jul 21;53(14):3985-93. doi: 10.1088/0031-9155/53/14/016. Epub 2008 Jul 3.

Abstract

This study investigates the efficacy of a new Fricke dosimeter formulation consisting of a standard Fricke gel dosimeter gelled with glucomannan (FrGDG). FrGDG was irradiated using a (192)Ir gamma-ray source with a remote afterloading system based on computed tomography images. (60)Co irradiation was performed for measuring the absorption of FrGDG and water. The distribution maps of T2 values from the irradiated containers were obtained by MR imaging and converted to the absorbed dose to visualize the dose distribution. We found that FrGDG was produced easily and quickly at room temperature. R2 (1/T2) values were reproducible and linearly correlated with the absorbed doses in the range from 0 to 30 Gy for irradiation with (192)Ir (the correlation coefficient was 0.99). The mean deviation between the doses obtained from the MR images of the FrGDG and those calculated by the treatment planning system for doses of 37.5, 40, 50, 62.5 and 75 Gy was 4.9%, 4.8%, 3.5%, 2.3% and 2.4%, respectively. In conclusion, MR imaging of FrGDG can visualize the dose distribution successfully, and thus serves as a useful quality assurance tool for complicated three-dimensional radiotherapy treatments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorption
  • Brachytherapy / methods*
  • Calibration
  • Gels / chemistry
  • Humans
  • Iridium Radioisotopes / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Mannans / chemistry*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / radiotherapy
  • Radiometry / methods*
  • Radiotherapy Dosage
  • Reproducibility of Results
  • Thermoluminescent Dosimetry

Substances

  • Gels
  • Iridium Radioisotopes
  • Mannans
  • (1-6)-alpha-glucomannan